Johns Hopkins Hospital treats first commercial TULSA-PRO case, expanding access to advanced prostate care

Profound Medical Corp.

Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using Profound's TULSA-PRO system.
Milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI suite.
TULSA-PRO delivers robotically controlled directional ultrasound under real-time MRI thermography to ablate prostate tissue.
Johns Hopkins was an early participant in the TACT and CAPTAIN trials that supported FDA clearance of TULSA-PRO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.